Lumida
/CLPT
⌘K
Clearpoint Neuro Inc

Clearpoint Neuro Inc

CLPT
$15.15USD↑+0.60%+0.09 today

MARKET CAP

454.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$14 – $15

52W RANGE

$8
$30

AI Summary

Stalk
StalkMedium

CLPT remains in a Stage 2 advancing corrective reset with clear higher highs and higher lows. Price is currently extended above rising short-term EMAs and in extreme overbought territory, and the late-June bearish exhaustion candle signals waning upside momentum and a likely pullback. Under a Speculative strategy, high asymmetry and defined structure are required, so patience is advised. A pullback toward the 9/21 EMA zone offers a more favorable entry for continuation participation.

  • ↑Q1 2026 revenue $12.1M, 43% YoY growth via organic sales and acquisitions
  • ↑Gross margin rose to 64% from 60% YoY
  • ↓Severely negative margins and weak profitability metrics persist
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

ClearPoint Neuro, Inc. (NASDAQ: CLPT) is a pioneering medical device company dedicated to developing innovative solutions for minimally invasive neurosurgical procedures. The company has a significant footprint within neurology, specifically focusing on the delivery of cell and gene therapies to the brain. ClearPoint aims to address unmet medical needs in this field by utilizing advanced technologies, thereby positioning itself as a hybrid device-biotech player at the intersection of device innovation and biopharmaceutical integration.

Bull says

  • ↑Q1 2026 revenue $12.1M, 43% YoY growth via organic sales and acquisitions
  • ↑Gross margin rose to 64% from 60% YoY
  • ↑Added Eraflow line and ERIS acquisition targeting double-digit segment growth
  • ↑Over 60 active biopharma partnerships expand drug delivery trials
  • ↑Positive analyst revisions signal improving earnings outlook
  • ↑Hybrid device-biotech model creates a strong niche competitive moat

Bear says

  • ↓Severely negative margins and weak profitability metrics persist
  • ↓Q1 2026 operational cash burn of $8M, cash down to $35.6M
  • ↓FDA regulatory uncertainty could delay product approvals
  • ↓CEO sold 20,000 shares, frequent dilution raises capital concerns
  • ↓High stock volatility deters risk-averse investors
  • ↓Focus on short-term breakeven raises long-term growth doubts

Investment themes with CLPT

Health Care Equipment & Supplies↑ +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-14-2026bullish

Transcript signals

Bull points

  • We remain both committed to and focused on developing a complete neuroecosystem capable of delivering various minimally invasive treatments, including cell and gene therapies to the brain.
  • Our company has started 2026 on a strong note by achieving record revenue of 12.1 million for the quarter, driven primarily by organic devices growth of 25%, which includes our historical drug delivery cannulas, navigation disposables, laser ablation applicators, capital systems, and software.
  • This revenue was complemented by inorganic device growth from our acquisition of the new Eraflow product line, which pushed our overall growth rate to 43% company-wide.

Bear points

  • Research and development costs were $4.5 million for the three months ended March 31, 2026, compared to $3.4 million for the same period in 2025, an increase of $1.1 million, or 34%, primarily due to higher personal costs and higher product and software development costs.
  • Sales and marketing expenses were $6.7 million for Q1 2026, compared to $3.8 million for the same period in 2025, an increase of $2.9 million or 75%, resulting from the expansion of our clinical and sales teams due to the IRIS integration.
Read full transcript analysis ›